The National Forum’s Value & Access Initiative Steering Committee and partners engaged in the value & access space provided input on the Institute for Clinical and Economic Review (ICER)’s scope of the upcoming assessment of the comparative clinical effectiveness and value of inclisiran (Novartis) and bempedoic acid (Nexletol™, Esperion Therapeutics, Inc.) for treatment of high cholesterol in the setting of heterozygous familial hypercholesterolemia or secondary prevention of ASCVD.